©Celoxica 2008. T: +44 (0)1235 863656
Press release
11 October 2007
Celoxica Implements Performance Acceleration for US Life-Sciences Company Increasing Momentum in Accelerated Computing Market
Celoxica Holdings plc (AIM: CXA) - a leading provider of FPGA based High Performance Computing solutions, announces the successful implementation of data analysis acceleration in the life sciences environment. Genetic analysis is a fundamental process in modern drug discovery and development but places great demands on data processing. Working with a respected US Life Sciences company, Celoxica was able to accelerate the client's gene sequencing algorithm by a factor of 20, significantly reducing this "bottleneck". The application of Celoxica's technology could have major benefits in the speed and cost of drug development.
This follows the announcement last month of two other successful proof of concept projects in the financial services market.
Lee Staines, Chief Executive of Celoxica commented, "We are delighted to announce the completion of another successful implementation within one of our key industry verticals. The ever increasing demand for higher performance coupled with a need for a reduction in power consumption is driving momentum in our market. We are seeing an increased level of awareness of our services within the financial services, life-sciences and oil and gas industries and believe the potential for our products to be significant."
ENQUIRIES
Celoxica Holdings plc
Tel. +44 (0)1235 863 656
Lee Staines, CEO
Michelle Young, CFO
ICIS
Tel. +44 (0) 20 7651 8688
Tom Moriarty
Caroline Evans-Jones
Arbuthnot
Tel. +44 (0) 20 7012 2000
Tom Griffiths
Alasdair Younie
Celoxica and the Celoxica logo are trademarks of Celoxica, Ltd. All other brand names and product names are the property of their respective owners
